Tuesday, September 11, 2018

Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges

Ann Gastroenterol. 2018 Sep-Oct;31(5):541-551. doi: 10.20524/aog.2018.0281. Epub 2018 Jun 4.

Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges
Vahe Shahnazariana, Daryl Ramaia,b, Madhavi Reddya, Smruti Mohantyc

Download full article: http://www.annalsgastro.gr/files/journals/1/earlyview/2018/ev-06-2018-01-AG_3988-0281.pdf
Article available online: Europe PMC (Open Access)

Hepatitis C virus (HCV) represents a global burden on healthcare that affects over 150 million people worldwide. In the past, HCV genotype 3 was considered difficult to treat relative to other genotypes. Genotype 3 has been associated with a higher rate of complications, including fatty liver disease, fibrosis, hepatocellular carcinoma and mortality. However, with the advent of first- and second-generation direct-acting antivirals, genotype 3 can be treated effectively. Additionally, these new drugs are well tolerated by patients and have significantly fewer side effects compared to ribavirin and interferon-based regimens. However, while great strides have been made in overcoming biological barriers, our next challenge lies in overcoming economic and financial obstacles if we are to eradicate HCV genotype 3. Herein, we review the clinical features associated with HCV genotype 3, current and emerging treatment regimens, and challenges associated with treatment.

Keywords Hepatitis C, genotype 3, sustained viral response, direct acting antivirals, treatment Ann Gastroenterol 2018; 31 (4): 1-11

Continue to article online.....

No comments:

Post a Comment